Gabriel Oh
YOU?
Author Swipe
View article: Scikick: A sidekick for workflow clarity and reproducibility during extensive data analysis
Scikick: A sidekick for workflow clarity and reproducibility during extensive data analysis Open
Reproducibility is crucial for scientific progress, yet a clear research data analysis workflow is challenging to implement and maintain. As a result, a record of computational steps performed on the data to arrive at the key research find…
View article: Correlation of Ultraviolet Radiation Levels With the Incidence of Cutaneous Squamous Cell and Merkel Cell Carcinomas in Non-sunbelt Locales in the United States: 2010-2017
Correlation of Ultraviolet Radiation Levels With the Incidence of Cutaneous Squamous Cell and Merkel Cell Carcinomas in Non-sunbelt Locales in the United States: 2010-2017 Open
Our results are limited by the completeness of the NOAA and SEER databases, and do not include basal cell carcinoma. Nevertheless, our data demonstrate that environmental factors, such as latitude in NSB locale and UVI indices, can affect …
View article: Supplementary Table 5. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 5. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
List of significant AA-DVPs.
View article: Supplementary Data from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Data from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
Supplementary methods, supplementary table legends, and all supplementary figures.
View article: Supplementary Table 1 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 1 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
Summary of samples retained and used for analysis after quality control: individual distribution across treatment visits, treatment follow-up visit times, and measured PSA levels.
View article: Data from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Data from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
Purpose: Primary resistance to abiraterone acetate (AA), a key medication for the treatment of metastatic castration-resistant prostate cancer, occurs in 20% to 40% of patients. We aim to identify predictive biomarkers for AA-treatm…
View article: Supplementary Table 2. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 2. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
Clinical information of all samples.
View article: Data from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Data from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
Purpose: Primary resistance to abiraterone acetate (AA), a key medication for the treatment of metastatic castration-resistant prostate cancer, occurs in 20% to 40% of patients. We aim to identify predictive biomarkers for AA-treatm…
View article: Supplementary Table 2. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 2. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
Clinical information of all samples.
View article: Supplementary Table 4. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 4. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
DAVID analysis of AA-DMPs at FDR q < 0.2 and AA-DVPs measured across patient groups for each visit.
View article: Supplementary Table 3 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 3 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
List of significant AA-DMPs at FDR q < 0.2.
View article: Supplementary Table 5. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 5. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
List of significant AA-DVPs.
View article: Supplementary Table 3 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 3 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
List of significant AA-DMPs at FDR q < 0.2.
View article: Supplementary Data from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Data from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
Supplementary methods, supplementary table legends, and all supplementary figures.
View article: Supplementary Table 4. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 4. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
DAVID analysis of AA-DMPs at FDR q < 0.2 and AA-DVPs measured across patient groups for each visit.
View article: Supplementary Table 1 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary Table 1 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
Summary of samples retained and used for analysis after quality control: individual distribution across treatment visits, treatment follow-up visit times, and measured PSA levels.
View article: Incorporating the “ <scp>4Ms</scp> ” framework to improve outpatient geriatric dermatology care
Incorporating the “ <span>4Ms</span> ” framework to improve outpatient geriatric dermatology care Open
According to the United States National Ambulatory Medical Care Survey (1993–2010), the majority of dermatology visits occurred in patients ≥55 years of age. Yet, geriatric dermatology is not currently part of the postgraduate core curricu…
View article: DiscoRhythm: an easy-to-use web application and R package for discovering rhythmicity
DiscoRhythm: an easy-to-use web application and R package for discovering rhythmicity Open
View article: DiscoRhythm: Removing Barriers to Biological Rhythm Discovery
DiscoRhythm: Removing Barriers to Biological Rhythm Discovery Open
View article: DiscoRhythm: an easy-to-use web application and R package for discovering rhythmicity
DiscoRhythm: an easy-to-use web application and R package for discovering rhythmicity Open
Motivation Biological rhythmicity is fundamental to almost all organisms on Earth and plays a key role in health and disease. Identification of oscillating signals could lead to novel biological insights, yet its investigation is impeded b…
View article: Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer’s disease pathology and cognitive symptoms
Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer’s disease pathology and cognitive symptoms Open
Epigenetic control of enhancers alters neuronal functions and may be involved in Alzheimer’s disease (AD). Here, we identify enhancers in neurons contributing to AD by comprehensive fine-mapping of DNA methylation at enhancers, genome-wide…
View article: Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease
Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease Open
Our findings suggest that loss of balance between cytosine methylation and demethylation during the circadian cycle can be a potential mechanism for complex disease. Additional experiments, however, are required to investigate the possible…
View article: Additional file 2: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease
Additional file 2: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease Open
Oscillation parameters for all interrogated CpG positions. EVC p value, cosinor p value, mesor, acrophase, amplitude, and genomic information for all interrogated cytosine positions. (CSV 40045 kb)
View article: Additional file 4: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease
Additional file 4: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease Open
MEME output for oscillating cytosines in neutrophil. Motif enrichment logos and characteristics for the sequences within 100 bp of osc-modCs. Generated using the MEME software tool. (HTML 2357 kb)
View article: Additional file 1: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease
Additional file 1: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease Open
Oscillation parameters of white blood cell fractions. Counts, fractions, and oscillation p values of 5 WBC cell types averaged across 4 individuals. (XLSX 9 kb)
View article: Additional file 7: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease
Additional file 7: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease Open
TOMTOM output for hyper-variable cytosines from populational neutrophil data. Motifs detected from sequences flanking hyper-variable cytosines in populational neutrophil data queried against a database of known vertebrate transcription fac…
View article: Additional file 6: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease
Additional file 6: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease Open
MEME output for hyper-variable cytosines from populational neutrophil data. Motif enrichment logos and characteristics for the sequences within 100 bp of hyper-variable cytosines from populational neutrophil data. Generated using the MEME …
View article: Additional file 3: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease
Additional file 3: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease Open
Proportion of variance explained by oscillations at various EVCs thresholds. Number of total EVCs, percent of oscillating EVCs, and summary of oscillating principal component scores at different EVC selection thresholds. (XLSX 9 kb)
View article: Additional file 5: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease
Additional file 5: of Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging, and complex disease Open
TOMTOM output for oscillating cytosines in neutrophil. Motifs detected from sequences flanking osc-modCs queried against a database of known vertebrate transcription factor sequence motifs. Significant matches are indicated beside each que…
View article: Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients Open
Purpose: Primary resistance to abiraterone acetate (AA), a key medication for the treatment of metastatic castration-resistant prostate cancer, occurs in 20% to 40% of patients. We aim to identify predictive biomarkers for AA-treatment res…